Large head metal-on-metal articulating surfaces of the hip are being used in increasing numbers of patients for oncological purposes due to the increased stability and reduced dislocation rate. Recent studies have raised many concerns over possible genotoxicity of MoM implants.
Adamantinoma is a rare low-grade malignant epithelial bone tumour. We report a case of an expansile, osteolytic mid-diaphyseal tibial lesion found in a 12 year-old girl. An initial histological diagnosis of basaloid-type adamantinoma was made. Following excision, further histology demonstrated basaloid cells and acellular matrix focally surrounded by osteoclast giant cells with calcium deposits, features consistent with pilomatrixoma. Several histological variants of adamantinoma have been documented; this case details a previously unreported histological adamantinoma variant –
This preliminary report demonstrates the effective use of Apapore in the management of benign cystic bone lesions. The use and development of bone graft substitutes over the past ten years has increased dramatically to improve their osseo-integration to a level similar to autografting techniques without the drawbacks of comorbidity from the graft site. Apapore is a synthetic bone graft substitute which consists of a scaffold of synthetic phase-pure hydroxy apatite with micro- and macroporosity and inter-connectivity to favour bone repair. Nineteen patients (12M:7F) with a mean age of 18.6years (8–33 years) having had procedures for the management of benign cystic lesions of bone with grafting using Apapore were followed up retrospectively for a mean period of 8 months (1–16months). In each case the diagnosis of a benign cystic lesion was made histologically prior to surgery. The subsequent definitive procedure was performed by a consultant on the Bone Tumour Unit at the Royal National Orthopaedic Hospital (Stanmore) in each case involving curettage and impaction of Apapore into the cavity in a standard fashion as a general anaesthetic procedure in the operating theatre. There have been no complications to date. All patients have made uneventful recoveries. Short-term radiological follow-up demonstrates excellent incorporation of the bone graft substitute and osseo-integration.
A case report of an 11 year old boy who underwent tibial osteotomy to prevent angulation of his right tibia. As a 7 year old, LH sufered a minor injury to his right tibia. A lump appeared at the same site. Soon the lump grew to be similar to “a second knee cap”. However, it only caused him pain when he traumatised it. He and his parents were disturbed by the lump, and the fact that it was creating an anterior-posterior bowing of his tibia. They sought medical advice. His original hospital carried out X rays that demonstrated the deformity and a cloud like lump at the tibial tuberosity. A bone scan confirmed a solitary osseous lesion. In July 2002 he was referred to the RNOH, where the decision was taken to resect the tibial tuberosity and undertake a corrective osteotomy. Post surgery in August 2002, LH was mobilised in a full cast for 9 weeks and graduated slowly from non to full weight bearing. Histology revealed a probable endchondroma, or unusual growth plate reaction. A year after the procedure LH is a symptom free, happy and active boy. Radiographs confirm normal angulation of his Tibia. In conclusion an osteotomy can be a very successful treatment for a childhood lesion that leads to progressive deformity.
We performed a retrospective analysis of massive endoprostheses inserted at our unit in the management of Giant Cell Tumours of the distal femur with a minimum follow up of 5 years.
Growing prostheses have been utilised in the United Kingdom since the late 1970s. Various mechanisms have been tried, but to date all have required some form of surgical intervention. This has led to multiple hospital admissions and a large amount of resources, both in theatre time and rehabilitation. Over the last ten years the Department of Bio-Medical Engineering at University College, London, together with the Royal National Orthopaedic Hospital, Stanmore, have developed a prosthesis which does not require surgical intervention to elongate. The total cost of the development has been something in the order of £350,000.00. The design features are the power worm screw mechanism where one turn equals 1 mm of elongation, but attached to this mechanism is an epicyclic gearbox, which has been reduced in size so that it can fit in to the body of the prosthesis. The speed reduction achieved by the gear box is 13061 to 1. The mechanism is capable of withstanding an axial load of 1,350 newtons. When an external magnetic field is applied an external coil speed of 3,000 revs per minute leads to a lengthening of 0.23 mm per minute. To date the prosthesis has been inserted in three patients ages 11, 12 and 13. All were suffering from osteosarcoma of the distal femur and had previously received neo-adjuvant chemotherapy. Early elongation had been achieved in all patients without any major discomfort and without the need for either analgesia or inpatient admission. There had been no loss of range of movement in the early post-lengthening period. This new prosthesis represents a significant advance in the management of skeletal sarcomas in children.